简体中文 | 繁體中文 | English

Quintiles 01

Quintiles Highlights Potential of Asia to Transform Biopharma

2012-03-15 15:44
  • zh_cn
  • zh_hant
  • en

Asia Chief Medical Officer cites need to ‘Understand local, think local and be local’

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--With the biopharmaceutical industry currently balanced atop tectonic plates, industry leaders must not settle on incremental innovation, but should look toward Asia as a unique opportunity for “radical transformation,” according to a paper from Quintiles, which says the need, the know-how, the resources and the will for innovation are all present in Asia.

“The pre-requisite, however, is that biopharmaceutical companies truly comprehend the emergence – or re-emergence – of Asia, and meet the challenge of understanding local, thinking local and being local,” writes the report’s author, Amar Kureishi, Regional Chief Medical Officer, Asia-Pacific, Quintiles.

Titled Tectonic Transformations: the Future of Biopharmaceuticals in Asia, the report says that a key element of the new biopharma model will be a renewed focus on alleviating individual suffering and addressing society’s healthcare needs.

“No longer will it suffice to develop an expensive new medicine which is accessible to only a small minority of patients, at a cost that siphons resources and leaves even larger healthcare issues unaddressed,” writes Kureishi. “The guiding question at the heart of the new model will be: How can science and technology create innovative solutions for patients that lead to healthier societies?”

Kureishi concludes that the role of Clinical Research Organizations (CROs) involves “bringing clinical research expertise and investments to tertiary care hospitals, crafting clinical development plans that address Asian medical needs, and nudging the evolving regulatory landscape in Asia in a direction that restores patients to the center of the healthcare system.”

About Quintiles

Quintiles is the only fully integrated biopharmaceutical services company offering, commercial, consulting and capital solutions worldwide. The Quintiles network of more than 20,000 engaged professionals in 60 countries works with an unwavering commitment to patients, safety and ethics. Quintiles helps biopharmaceutical companies navigate risk and seize opportunities in an environment where change is constant. For more information, please visit www.quintiles.com.

Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50203082&lang=en

 

Contacts

Quintiles
Asia Pacific
Stacey Hara, +65 6602 1583
Media Relations
stacey.hara@quintiles.com
or
Jay Johnson, +1 919-998-2066
Media Relations
jay.johnson@quintiles.com
or
Greg Connors, +1 919-998-2000
Investor Relations
invest@quintiles.com

 

 

Dr. Amar Kureishi, Chief Medical Officer and Head of Drug Development, Quintiles Asia. (Photo: Business Wire)